期刊文献+

阿拉瑞林对子宫内膜癌裸鼠移植瘤作用的实验研究

The experimental study of alarelin to xenograft of nude mice in endometrial cancer
下载PDF
导出
摘要 目的观察阿拉瑞林对HEC-1B裸鼠移植瘤的抑制作用及对血管内皮生长因子(VEGF)表达的影响。方法将HEC-1B荷瘤鼠随机分为5组:阴性对照组、阿拉瑞林低、中、高剂量组和阳性对照(5-Fu)组。30d后处死裸鼠,称取移植瘤质量,并观察抑瘤率及用免疫组化SABC法检测移植瘤VEGF的表达。结果阿拉瑞林组和5-Fu组平均瘤质量和抑瘤率与阴性对照组比较,差异均有统计学意义(P<0.05或P<0.01)。低、中剂量阿拉瑞林组VEGF阳性率与阴性对照组比较,差异有统计学意义(P<0.05);高剂量阿拉瑞林组、5-Fu组VEGF阳性率与阴性对照组比较,差异有统计学意义(P<0.01)。结论阿拉瑞林有一定的抑制子宫内膜癌生长的作用,且不良反应轻微,可能通过对VEGF的表达调控来实现。 Objective To observe the effect of alarelin in inhibiting the growth of transplanting HEC-1B cells in nude mice and the expression of VEGF. Methods Nude mice with transplanted HEC-1B tumor were randomly divided into five groups:Negative control group,alarelin low,middle and high-dose group and positive control(5-Fu) group. After 30 days,the nude mice were executed,then the tumor was weighed,the inhibitive rates of the tumor in nude mice was observed and immu-nohistochemistry with SABC staining method were used to detect the expression of VEGF. Results Average tumor quality and inhibition rate of alarelin group and 5-Fu group compared with that of negative control group,the differences were statistically significant(P 0. 05 or P 0. 01). VEGF-positive rate of alarelin low,middle-dose group compared with the negative control group,the difference was statistically significant(P 0. 05);VEGF-positive rate of alarelin high-dose group and 5-Fu group compared with the negative control group,the difference was statistically significant( P 0. 01). Conclusion Alarelin has good effect in inhibiting the growth of endometrial cancer by regulating VEGF expression.
出处 《临床合理用药杂志》 2010年第9期49-50,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 子宫内膜癌 阿拉瑞林 移植瘤 裸鼠 血管内皮生长因子 Endometrial cancer Alarelin Xenograft Nude mice VEGF
  • 相关文献

参考文献4

二级参考文献29

  • 1张玉泉,曹斌融,周先荣,张惜阴.丙氨瑞林治疗子宫内膜癌病人的性激素及有丝分裂指数的变化[J].新药与临床,1996,15(4):194-196. 被引量:9
  • 2张玉泉.GnRH-A作用于卵巢肿瘤的研究[J].国外医学(妇产科学分册),1997,24(1):27-30. 被引量:10
  • 3[1]Lahlou N.Pharmacokinetics and pharmacodynamics of triptorelin.Ann Urol(Paris),2005,39:S78-S84.
  • 4[2]Carel JC.Treatment of precocious puberty by GnRH agonists.Ann Urol(Paris),2005,39:S85-S88.
  • 5[3]Hirsch HJ,Gillis D,Strich D,et al.The histrelin implant:a novel treatment for central precocious puberty.Pediatrics,2005,116:e798-e802.
  • 6[4]Sarah K,Zvi N,Rony S,et al.Gonadotropin-releasing hormone in apoptosis of prostate cancer cells.Cancer Letters,2006,234:109-123.
  • 7[5]Ratcliffe KE,Fraser HM,Sellar R,et al.Bifunctional Gonadotropin-Releasing Hormone Antagonist-Progesterone Analogs with Increased Efficacy and Duration of Action.Endocrinology,2006,147:571-579.
  • 8[6]Smith MR,Lee WC,Brandaman J,et al.Gonadotropin-releasing hormone agonists and fracture risk:a claims-based cohort study of men with nonmetastatic prostate cancer.J Clin Oncol,2005,23:7897-7903.
  • 9[7]Andrea DL,Marianna DF,Fabrizio P,et al.Clinical Response,Vascular Change,and Angiogenesis in Gonadotropin-Releasing Hormone Analogue-Treated Women With Uterine Myomas.J Soc Gynecol Investig,2005,12:123-128.
  • 10[8]Sallam HN,Garcia-Velasco JA,Dias S,et al.Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis.Cochrane Database Syst Rev,2006,1:4635-4636.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部